Anti-capsule human monoclonal antibodies protect against hypervirulent and pandrug-resistant Klebsiella pneumoniae
Roscioli, E.; Zucconi Galli Fonseca, V.; Bosch, S. S.; Paciello, I.; Maccari, G.; Batani, G.; Stazzoni, S.; Cardinali, G.; Tiseo, G.; Giordano, C.; Shen, Y.; Capoccia, L.; Ridelfi, M.; Troisi, M.; Manganaro, N.; Mugnaini, C.; Cardamone, D.; De Santi, C.; Ciabattini, A.; Cerofolini, L.; Fragai, M.; Licastro, D.; Nicolau, D. P.; Abdelraouf, K.; Barnini, S.; Menichetti, F.; Falcone, M.; Sala, C.; Kabanova, A.; Rappuoli, R.
Show abstract
The silent pandemic caused by antimicrobial resistance (AMR) requires innovative therapeutic approaches. Human monoclonal antibodies (mAbs), which are among the most transformative, safe and effective drugs in oncology and autoimmunity, are rarely used for infectious diseases and not yet used for AMR. Here we applied an antigen-agnostic strategy to isolate extremely potent human mAbs against Klebsiella pneumoniae (Kp) sequence type 147 (ST147), a hypervirulent and pandrug-resistant clonotype which is spreading globally. Isolated mAbs target the bacterial capsule and the O-antigen. Surprisingly, although both capsule- and O-antigen-specific mAbs displayed bactericidal activity in the picomolar range in vitro, only the capsule-specific mAbs were protective against fulminant ST147 bloodstream infection. Protection correlated with in vitro bacterial uptake by macrophages and enchained bacterial growth. Our study describes the only drug able to protect against pandrug-resistant Kp and provides a strategy to isolate mAbs and identify correlates of protection against AMR bacteria.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex 95%
- citrOgen: a synthesis-free polysaccharide and protein antigen-presentation to antibody-induction platform 95%
- Prophage exotoxins enhance colonization fitness in epidemic scarlet fever-causing Streptococcus pyogenes 94%
Similar papers in this journal
- Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination 94%
- Crimean-Congo Hemorrhagic Fever Survivors Elicit Protective Non-Neutralizing Antibodies that Target 11 Overlapping Regions on Viral Glycoprotein GP38 94%
- Deep repertoire mining uncovers ultra-broad coronavirus neutralizing antibodies targeting multiple epitopes 94%
Similar papers in this journal
- Hybrid immunity shifts the Fc-effector quality of SARS-CoV-2 mRNA vaccine-induced immunity 94%
- Surface-modified measles vaccines encoding oligomeric, fusion-stabilized SARS-CoV-2 spike glycoproteins bypass measles seropositivity, boosting neutralizing antibody responses to omicron and historical variants. 93%
- SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients 93%
Similar papers in this journal
- A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant 94%
- Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates 93%
- Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.